CONTENTS VOL. 19, 2001

Volume 19, No. 1

Preclinical Studies

Chronic oral administration of CI-994: a Phase 1 study – S. Prakash, B.J. Foster, M. Meyer, A. Wozniak, L.K. Heilbrun, L. Flaherty, M. Zalupski, L. Radulovic, M. Valdivieso, P.M. LoRusso 1–11

Phase I study of Irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia – F. Giles, J. Cortes, G. Garcia-Manero, S. Kornblau, E. Estey, M. Kwari, A. Murgo, H. Kantarjian 13–20

A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignancies – C.D. Blanke, M. Stipanov, J. Morrow, M. Rothenberg, R. Chinery, Y. Shyr, R. Coffey, D.H. Johnson, S.D. Leach, R.D. Beauchamp 21–27

Phase 1 study of N^1-N^{11}-diethylnorspermine (DENSPM) administered TID for 6 days in patients with advanced malignancies – R.R. Streiff, J.F. Bender 29–39

Clinical Review

The oral fluorinated pyrimidines – J.S. de Bono, C.J. Twelves 41–59

Clinical Pharmacology

Factors affecting the pharmacokinetics of CPT-11: The Body Mass Index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11 – T. Miya, T. Goya, H. Fujii, T. Ohtsu, K. Itoh, T. Igarashi, H. Minami, Y. Sasaki 61–67

Phase II Studies

Phase II study of 4-Ipomeanol, a naturally occurring alkylating furan, in patients with advanced hepatocellular carcinoma – S. Lakhanpal, R.C. Donehower, E.K. Rowinsky 69–76

A phase II trial of pyrazoloacridine (PZA) in squamous carcinoma of the cervix – A Gynecologic Oncology Group Study S.C. Plaxe, J.A. Blessing, J.A. Lucci, J.A. Hurteau 77–80

Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma – W.S. Kim, M.M. Kim, H.J. Choi, S.-S. Yoon, M.H. Lee, K. Park, C.H. Park, W.K. Kang 81–83

A Phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with advanced non-small cell cancer previously treated with chemotherapy – J.E. Dowell, D.H. Johnson, J.S. Rogers, Y. Shyr, N. McCullough, P. Krozely, R.F. DeVore 85–88

Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: A report of two clinical trials of the Eastern Cooperative Oncology Group – B.J. Giantonio, H. Hochster, R. Blum, P.H. Wiernik, G.R. Hudes, J. Kirkwood, D. Trump, M.M. Oken 89–92

Excellent response to gemcitabine in a massively pre-treated woman with extensive cutaneous involvement after recurrence of breast cancer – J. Arends, C. Unger 93–100

Achievement of complete remission in refractory Hodgkin's disease with prolonged infusion of gemcitabine – O. Sezer, J. Eucker, C. Jakob, O. Kaufmann, P. Schmid, K. Possinger 101–104

Volume 19, No. 2

Introduction: Recent topics in the clinical pharmacology of taxanes that might change future perspectives – A. Sparreboom, J. Verweij 111–112

Determinants of paclitaxel uptake, accumulation and retention in solid tumors – S.H. Jang, M.G. Wientjes, J.L.-S. Au 113–123

Role of formulation vehicles in taxane pharmacology – L. van Zuylen, J. Verweij, A. Sparreboom 125–141

Progress in the development of alternative pharmaceutical formulations of taxanes – B. Nuijen, M. Bouma, J.H.M. Schellens, J.H. Beijnen 143–153

Oral delivery of taxanes – M.M. Malingré, J.H. Beijnen, J.H.M. Schellens 155–162

Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel – R. Bruno, N. Vivier, C. Veyrat-Follet, G. Montay, G.R. Rhodes 163–169

Body surface area as a determinant of pharmacokinetics and drug dosing – M. Sawyer, M.J. Ratain 171–177

Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy – L. Vigano, A. Locatelli, G. Grasselli, L. Gianni 179–196

Volume 19, No. 3

Preclinical studies

In vitro activity of liposomal N^4octadecyl-1-β-D-arabinofurano-sylcytosine (NOAC), a new lipophilic derivative of 1-β-D-arabino-furanocylcytosine on biopsized clonogenic human tumor cells and hematopoietic precursor cells – R.A. Schwendener, K. Friedl, H. Depenbrock, H. Schott, A.-R. Hanauske 203–210

Tetramethylpiperidine-substituted phenazines inhibit the proliferation of intrinsically multidrug resistant carcinoma cell lines – E. van Niekerk, J.F. O'Sullivan, G.K. Jooné, C.E.J. van Rensburg 211–217

Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells – K. Fukuoka, J. Usuda, Y. Iwamoto, H. Fukumoto, T. Nakamura, T. Yoneda, N. Narita, N. Saijo, K. Nishio 219–227

Phase II studies

Altretamine for the treatment of metastatic renal cell carcinoma: A Hoosier Oncology Group trial – R.T. Zon, J. McClean, D. Helman, R. Ansari, J. Picus, A. Sandler, S.D. Williams, P.J. Loehrer Sr. 229–231

N-Methylformamide in advanced squamous cancer of the uterine cervix: An Eastern Cooperative Oncology Group phase II trial – L. Rajdev, Z.-F. Yu, S. Wadler, E. Weller, S. Benham Kahn, D. Tormey, R. Skeel, P.H. Wiernik 233–237

Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy: A Southwest Oncology Group study – R.P. Whitehead, J.M. Unger, L.E. Flaherty, J.R. Eckardt, S.A. Taylor, M.S. Didolkar, W. Samlowski, V.K. Sondak 239–243

Phase II study of bryostatin 1 in patients with relapsed multiple myeloma – M.L. Varterasian, P.A. Pemberton, K. Hulburd, D.H. Rodriguez, A. Murgo, A.M. Al-Katib 245–247

Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer – B. Brockstein, B. Samuels, R. Humerickhouse, R. Arietta, P. Fishkin, J. Wade, J. Sosman, E.E. Vokes 249–254

A phase II trial of weekly intravenous ranpirnase (Onconase®), a novel ribonuclease in patients with metastatic kidney cancer – N.J. Vogelzang, M. Aklilu, W.M. Stadler, M.C. Dumas, S.M. Mikulski 255–260

Phase II trial of GM-CSF in advanced prostate cancer – R. Dreicer, W.A. See, E.A. Klein 261–265

Volume 19, No. 4

Preclinical studies

Compatibility and stability of the investigational polypeptide marine anticancer agent kahalalide F in infusion devices – B. Nuijen, M. Bouma, C. Manada, J.M. Jimeno, L.L. Lazaro, A. Bult, J.H. Beijnen 273–281

Changes in prostate-specific antigen (PSA) level correlate with growth inhibition of prostate cancer cells treated *in vitro* with a novel anticancer drug, irofulven – B.A. Woynarowska, A.L. Higdon, R.M. Muñoz, P. Bushong, S.J. Waters 283–291

Gene expression profiling of exposure to TZT-1027, a novel microtubule-interfering agent, in non-small cell lung cancer PC-14 cells and astrocytes – T. Natsume, T. Nakamura, Y. Koh, M. Kobayashi, N. Saijo, K. Nishio 293–301

Phase I study

A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest – C.M. George, D.J. Haraf, A.M. Mauer, S.A. Krauss, P.C. Hoffman, C.M. Rudin, L. Szeto, E.E. Vokes 303–310

Phase II studies

Evaluation of gemcitibine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A Southwest Oncology Group Phase II study – W.E. Samlowski, H. Gundacker, J.P. Kuebler, J.K. Giguere, G.M. Mills, D.E. Schuller, J.F. Ensley 311–315

Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma – W.J. Berg, L. Schwartz, R. Yu, M. Mazumdar, R.J. Motzer 317–320

Phase II trial of 9-aminocamptothecin as a 72-h infusion in cutaneous T-cell lymphoma – A. Argiris, P. Heald, T. Kuzel, F.M. Foss, S. DiStasio, D.L. Cooper, S. Arbuck, J.R. Murren 321–326

Phase II study of pyrazoloacridine in metastatic renal cell carcinoma – J.P. Kuebler, G.W. King, P. Triozzi, T. Moore, E.H. Kraut 327–328

A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer – E.E. Vokes, G.S. Gordon, C.M. Rudin, A.M. Mauer, S. Watson, S. Krauss, R. Arrieta, H.M. Golomb, P.C. Hoffman 329–333

Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium – K. Margolin, J. Longmate, T.W. Synold, D.R. Gandara, J. Weber, R. Gonzalez, M.J. Johansen, R. Newman, T. Baratta, J.H. Doroshow 335–340

Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea – B. Pro, R. Lozano, J.A. Ajani 341–343

Contents Volume 19, 2001 345-347

Author Index 349–350

Instructions for authors 351–355